VBIVQ — VBI Vaccines Share News
0.000.00%
Last trade - 00:00- $0.01m
- $36.16m
- $8.68m
Brief: VBI Vaccines Says PreHevbrio Available In U.S.
VBI Vaccines Inc reports results for the quarter ended in December - Earnings Summary
Brief: VBI Vaccines Reports Q4 Results, Provides Outlook For 2022
VBI Vaccines Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: VBI Vaccines Says Its Hepatitis B Vaccine Recommended By CDC Advisory Committee
Brief: VBI Vaccines Announces Dosing Of First Patient In Second Phase 2 Study In Chronic Hepatitis B Patients As Part Of Expansion Of Clinical Collaboration With Brii Bio
U.S. RESEARCH ROUNDUP-Akamai Technologies, Metacrine, Vaxcyte
Brief: VBI Vaccines Announces Filing Of New Drug Submission For 3-Antigen Hepatitis B Vaccine To Health Canada
Brief: VBI Vaccines To Present New Overall Survival Data From Phase 2A Study In Recurrent GBM
U.S. STOCKS ON THE MOVE-Ambarella, BeyondSpring, OceanPal, Allbirds
U.S. STOCKS ON THE MOVE-Box, BeyondSpring, Build-A-Bear Workshop, OceanPal
U.S. STOCKS ON THE MOVE-CTI BioPharma, Aditxt, OceanPal, Ardelyx
VBI Vaccines jumps on hepatitis B shot approval
Brief: VBI Vaccines Announces FDA Approval Of PreHevbrio For Prevention Of Hepatitis B
VBI Vaccines Inc reports results for the quarter ended in September - Earnings Summary
Brief: VBI Vaccines Announces Q3 Loss Per Share Of $0.06
VBI Vaccines Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: VBI Vaccines Announces E-Poster Presentation Of 3-Antigen Prophylactic Hepatitis B Vaccine Data At The Liver Meeting® 2021
VBI Vaccines Inc expected to post a loss of 7 cents a share - Earnings Preview